Regeneron Pharmaceuticals, Inc. (BIT:1REGN)
Italy · Delayed Price · Currency is EUR | Market Cap | 58.62B +15.9% |
| Revenue (ttm) | 12.94B +5.9% |
| Net Income | 3.84B -1.7% |
| EPS | 35.61 +4.1% |
| Shares Out | n/a |
| PE Ratio | 15.28 |
| Forward PE | 12.83 |
| Dividend | 3.11 (0.52%) |
| Ex-Dividend Date | May 19, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 582.70 |
| Day's Range | n/a |
| 52-Week Range | 467.50 - 697.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
The Scientist With 1,000 Patents Fueling a Drug Powerhouse
At Regeneron, George Yancopoulos is the rare scientist and executive who drives growth with discoveries instead of acquisitions.
$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FD...
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $REGN #BFA--Regeneron Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA.
Regeneron price target raised to $1,000 from $995 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron (REGN) to $1,000 from $995 and keeps a Buy rating on the shares. The firm is revising some of…
REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Biohaven enters into clinical supply agreement with Regeneron
Biohaven (BHVN) has entered into a clinical supply agreement with Regeneron Pharmaceuticals (REGN) to evaluate the combination of BHV-1530 and cemiplimab, or Libtayo, in patients with solid tumors bas...
Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings
Booking Holdings, Alphabet, and six other companies have underperformed their sectors despite improving earnings expectations, setting up potential upside during second-quarter earnings season.
Regeneron’s dupilumab granted orphan drug designation
Regeneron’s (REGN) dupilumab was granted FDA orphan drug designation, according to a post on the agency’s website.
Regeneron price target lowered to $856 from $860 at BofA
BofA analyst Tazeen Ahmad lowered the firm’s price target on Regeneron (REGN) to $856 from $860 and keeps a Buy rating on the shares. Steady Eylea HD demand growth is…
Regeneron price target lowered to $854 from $855 at Piper Sandler
Piper Sandler analyst Biren Amin lowered the firm’s price target on Regeneron (REGN) to $854 from $855 and keeps an Overweight rating on the shares. The firm updates its model…
Regeneron price target lowered to $730 from $788 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $730 from $788 and keeps an Equal Weight rating on the shares. Biotech could benefit from…
Regeneron price target lowered to $769 from $778 at Truist
Truist lowered the firm’s price target on Regeneron (REGN) to $769 from $778 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Regeneron price target lowered to $696 from $707 at RBC Capital
RBC Capital lowered the firm’s price target on Regeneron (REGN) to $696 from $707 and keeps a Sector Perform rating on the shares as part of a broader research note…
Regeneron price target lowered to $800 from $990 at HSBC
HSBC lowered the firm’s price target on Regeneron (REGN) to $800 from $990 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target…
Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Regeneron (REGN) to $750 from $785 and keeps an Overweight rating on the shares. Large-cap biopharmas are expected to…
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing fa...
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says
Eli Lilly (LLY), Regeneron (REGN), Amneal (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s PreCheck pilot progr...
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck...
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursda...
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
RBC Capital keeps a Sector Perform rating and a $707 price target on Regeneron (REGN) but notes that the acquisition of Apogee Therapeutics (APGE) by AbbVie (ABBV) announced this morning…
Regeneron announces FDA, EMA accept cemdisiran submissions for review
Regeneron (REGN) announced that both the FDA and European Medicines Agency, or EMA, have accepted the regulatory applications for cemdisiran to treat adult patients with generalized myasthenia gravis,...
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing
Regeneron Pharmaceuticals Transcript: AGM 2026
The meeting approved all board proposals, including director elections, auditor ratification, and executive compensation. Strong financial growth was reported, with significant R&D investment and pipeline expansion highlighted. No shareholder questions were submitted.
Regeneron Pharmaceuticals Slides: FY 2026
Regeneron Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 12, 2026.